Drugs / DZD1516
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04509596 | Sep 2020 → Jul 2022 | breast cancer | Dizal Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2023-07-09 | Dizal Pharmaceuticals | Results Dizal Announces Pre-clinical and Early Clinical Results of DZD1516 in Breast Cancer Research dizalpharma.com ↗
Dizal today announced the latest publication of translational science and early clinical results of DZD1516, a potent andselective HER2 tyrosine kinase inhibitor (TKI) with full brain blood barrier (BBB) penetration in Breast Cancer Research (IF: 8.4). |
| 2022-12-09 | Dizal Pharmaceuticals | Results 2022 SABCS| Dizal Announces Updated Results from Phase I Trial Evaluating DZD1516 in Heavily Pretreated Metastatic HER2 Positive Metastatic Breast Cancer dizalpharma.com ↗
Among 21 evaluable patients who completed at least one post-treatment assessment per modified RECIST v1.1 criteria, the best anti-tumor response achieved with the oral HER2-targeted TKI was stable disease in intracranial, extracranial, and overall lesions. |
| 2022-11-02 | Dizal Pharmaceuticals | Results Dizal to Present Latest Scientific Advancements across its Fast-growing Innovative Pipeline at 2022 CSCO dizalpharma.com ↗
With a median of 7 lines of prior systemic treatment (86% treated with HER2 TKI), the best antitumor efficacy in intracranial, extracranial and overall lesions was stable disease. |
| 2022-09-05 | Dizal Pharmaceuticals | Results Dizal Announces Positive Phase I Clinical Trial Results for DZD1516 in Treating HER2 Breast Cancer at 2022 ESMO dizalpharma.com ↗
DZD1516 was well tolerated at doses ≤ 250 mg, and in consistent with its high selectivity, no wild-type EGFR-related AEs have been reported. |
| 2022-05-27 | Dizal Pharmaceuticals | Results Dizal to Demonstrate the Strength and Rapid Acceleration of its Clinical Portfolio at ASCO 2022 dizalpharma.com ↗
Results from the Phase 1 trial, which is evaluating the safety and tolerability of DZD1516 in patients with metastatic HER2 positive breast cancer, showed DZD1516 was well tolerated at doses < 300mg, BID. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-07-09 | Dizal Pharmaceuticals | Dizal Announces Pre-clinical and Early Clinical Results of DZD1516 in Breast Cancer Research dizalpharma.com ↗ |
| 2022-12-09 | Dizal Pharmaceuticals | 2022 SABCS| Dizal Announces Updated Results from Phase I Trial Evaluating DZD1516 in Heavily Pretreated Metastatic HER2 Positive Metastatic Breast Cancer dizalpharma.com ↗ |
| 2022-11-02 | Dizal Pharmaceuticals | Dizal to Present Latest Scientific Advancements across its Fast-growing Innovative Pipeline at 2022 CSCO dizalpharma.com ↗ |
| 2022-09-05 | Dizal Pharmaceuticals | Dizal Announces Positive Phase I Clinical Trial Results for DZD1516 in Treating HER2 Breast Cancer at 2022 ESMO dizalpharma.com ↗ |
| 2022-05-27 | Dizal Pharmaceuticals | Dizal to Demonstrate the Strength and Rapid Acceleration of its Clinical Portfolio at ASCO 2022 dizalpharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DZD1516 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04509596 ↗ |
| Action | Inhibit | “DZD1516 is an oral, blood brain barrier penetrable, selective HER2 tyrosine kinase inhibitor.” NCT04509596 ↗ |
| Route | Oral | “Part A is twice daily (except Cycle 0) oral dosing of DZD1516, starting from 50 mg.” NCT04509596 ↗ |